Login Register Cart 0
Generic placeholder image

Current Signal Transduction Therapy

Editor-in-Chief

ISSN (Print): 1574-3624
ISSN (Online): 2212-389X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In Silico Identification of Human miR-26a-1 from Hypertension Genome Sequence

Author(s): K. Auxzilia Preethi, Sushmaa Chandralekha Selvakumar and Durairaj Sekar*

Volume 18, Issue 1, 2023

Published on: 25 October, 2022

Article ID: e270822208077 Pages: 5

DOI: 10.2174/1574362417666220827114844

Price: $65

Abstract

Background: Hypertension is a global public health issue that is becoming more prevalent. It is a non-communicable disease and a great public health problem affecting almost half of the world’s adult population. Being multifactorial, hypertension is a key risk factor for stroke, coronary artery disease, heart failure, and chronic renal failure. However, the cellular and molecular mechanisms that regulate it remain mostly unknown. According to numerous studies, microRNAs (miRNAs) have been implicated in a range of cellular processes in the development of illnesses. The current study aims to identify miRNAs in hypertension from genome sequences found in public genomic databases.

Materials and Methods: In this study, we have used bioinformatic approaches to identify miR-26a- 1 for hypertension using the NCBI database, miRBase and target scan. Finally, the RNA fold was used to create the secondary structure of miR-26a-1.

Results and Discussion: Careful evaluation of secondary structure result showed that hsa-miR- 26a-1 has a minimum free energy of - 37.30 kcal. The correlation between miR-26a-1 and hypertension genome sequence was identified.

Conclusion: These computational approaches have concluded that miR-26a-1 can be used as a diagnosis, prognosis and effective therapeutic target for treating hypertension. Thus, further research could enlighten the role of miR-26a-1 in hypertension.

Keywords: Hypertension, miRNAs, biomarkers, therapeutic target, hsa-miR-26a-1, heart failure.

Graphical Abstract

[1]
Sekar D, Shilpa BR, Das AJ. Relevance of microRNA 21 in different types of hypertension. Curr Hypertens Rep 2017; 19(7): 57.
[http://dx.doi.org/10.1007/s11906-017-0752-z] [PMID: 28597404]
[2]
Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Can J Cardiol 2018; 34(5): 575-84.
[http://dx.doi.org/10.1016/j.cjca.2017.12.005] [PMID: 29459239]
[3]
Adler AJ, Prabhakaran D, Bovet P, et al. Reducing cardiovascular mortality through prevention and management of raised blood pressure: A world heart federation roadmap. Glob Heart 2015; 10(2): 111-22.
[http://dx.doi.org/10.1016/j.gheart.2015.04.006] [PMID: 26213298]
[4]
Wu G, Jose PA, Zeng C. Noncoding RNAs in the regulatory network of hypertension. Hypertension 2018; 72(5): 1047-59.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.118.11126] [PMID: 30354825]
[5]
Bartel DP. Metazoan microRNAs. Cell 2018; 173(1): 20-51.
[http://dx.doi.org/10.1016/j.cell.2018.03.006] [PMID: 29570994]
[6]
Li Z, Rana TM. Therapeutic targeting of microRNAs: Current status and future challenges. Nat Rev Drug Discov 2014; 13(8): 622-38.
[http://dx.doi.org/10.1038/nrd4359] [PMID: 25011539]
[7]
Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary microRNAs by the microprocessor complex. Nature 2004; 432(7014): 231-5.
[http://dx.doi.org/10.1038/nature03049] [PMID: 15531879]
[8]
Kobayashi H, Tomari Y. RISC assembly: Coordination between small RNAs and argonaute proteins. Biochim Biophys Acta 2016; 1859(1): 71-81.
[http://dx.doi.org/10.1016/j.bbagrm.2015.08.007] [PMID: 26303205]
[9]
Raftopoulos L, Katsi V, Makris T, Tousoulis D, Stefanadis C, Kallikazaros I. Epigenetics, the missing link in hypertension. Life Sci 2015; 129: 22-6.
[http://dx.doi.org/10.1016/j.lfs.2014.08.003] [PMID: 25128856]
[10]
Saravanan S, Islam VI, Thirugnanasambantham K, Sekar D. In silico identification of human miR 3654 and its targets revealed its involvement in prostate cancer progression. MicroRNA 2016; 5(2): 140-5.
[http://dx.doi.org/10.2174/2211536605666160610094230] [PMID: 27297584]
[11]
Sekar D. Comment on the potential role of microRNAs in hypertension. J Hum Hypertens 2018; 32(10): 639-40.
[http://dx.doi.org/10.1038/s41371-018-0104-8] [PMID: 30232397]
[12]
Yang F, Li H, Du Y, Shi Q, Zhao L. Downregulation of microRNA 34b is responsible for the elevation of blood pressure in spontaneously hypertensive rats. Mol Med Rep 2017; 15(3): 1031-6.
[http://dx.doi.org/10.3892/mmr.2017.6122] [PMID: 28098882]
[13]
Li H, Yang Z, Gao F, Zhang Y, Meng W, Rong S. MicroRNA-17 as a potential diagnostic biomarker in pulmonary arterial hypertension. J Int Med Res 2020; 48(6)300060520920430
[http://dx.doi.org/10.1177/0300060520920430] [PMID: 32600075]
[14]
Johnson J, Lakshmanan G, Biruntha M, Vidhyavathi RM, Kalimuthu K, Sekar D. Computational identification of MiRNA-7110 from pulmonary arterial hypertension (PAH) ESTs: A new microRNA that links diabetes and PAH. Hypertens Res 2020; 43(4): 360-2.
[http://dx.doi.org/10.1038/s41440-019-0369-5] [PMID: 31792346]
[15]
Zhang X, Wang X, Wu J, et al. The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis. Biosci Rep 2018; 38(4)BSR20180525
[http://dx.doi.org/10.1042/BSR20180525]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy